Villalobos Violán, V. et al. 2023. Real-life experience after 3 months with tezepelumab before marketing approval. Allergologia et Immunopathologia. 52, 2 (Mar. 2023), 80–82. DOI:https://doi.org/10.15586/aei.v52i2.1063.